MedTrace Logo

Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

NCT04530318 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-19

No results posted yet for this study

Summary

The aim of this project is to assess properly the clinical efficacy of TolDec therapy by imaging, clinical and surrogate end-points related with the activity of the disease.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

OTHER

Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded

The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).

OTHER

Placebo

The infusion of the cells / placebo will take place at the Hospital Clínic de Barcelona (weeks 0, 2 and 4).

Sponsors & Collaborators

  • Judit Pich

    lead OTHER

Principal Investigators

  • Yolanda Blanco, MD · Hospital Clinic of Barcelona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-27
Primary Completion
2025-09-09
Completion
2026-03-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530318 on ClinicalTrials.gov